Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Cold conditions decrease it
The injection typically contains two key components: an anesthetic for immediate pain relief and a corticosteroid to reduce inflammation around irritated nerves
This represents a niche application distinct from the systemic effects sought with nasal or injectable administration
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
US$ 20.88
US$ 24.16
US$ 24.25
